226 related articles for article (PubMed ID: 10605734)
1. Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor.
Ikeda Y
Thromb Haemost; 1999 Aug; 82(2):435-8. PubMed ID: 10605734
[No Abstract] [Full Text] [Related]
2. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.
Liu Y; Shakur Y; Yoshitake M; Kambayashi Ji J
Cardiovasc Drug Rev; 2001; 19(4):369-86. PubMed ID: 11830753
[TBL] [Abstract][Full Text] [Related]
3. Cilostazol for intermittent claudication.
Med Lett Drugs Ther; 1999 May; 41(1052):44-6. PubMed ID: 10368703
[No Abstract] [Full Text] [Related]
4. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication.
Lee TM; Su SF; Tsai CH; Lee YT; Wang SS
Clin Sci (Lond); 2001 Sep; 101(3):305-11. PubMed ID: 11524048
[TBL] [Abstract][Full Text] [Related]
5. Cilostazol: treatment of intermittent claudication.
Reilly MP; Mohler ER
Ann Pharmacother; 2001 Jan; 35(1):48-56. PubMed ID: 11197586
[TBL] [Abstract][Full Text] [Related]
6. Cilostazol approved for use in intermittent claudication.
Miller JL
Am J Health Syst Pharm; 1999 Mar; 56(5):404. PubMed ID: 10096695
[No Abstract] [Full Text] [Related]
7. The role of cilostazol (Pletal) in the management of intermittent claudication.
Bradbury AW
Int J Clin Pract; 2003 Jun; 57(5):405-9. PubMed ID: 12846346
[TBL] [Abstract][Full Text] [Related]
8. Cilostazol.
Cheng JW
Heart Dis; 1999; 1(3):182-6. PubMed ID: 11720622
[TBL] [Abstract][Full Text] [Related]
9. Cilostazol in the management of vascular disease.
Dalainas I
Int Angiol; 2007 Mar; 26(1):1-7. PubMed ID: 17353881
[TBL] [Abstract][Full Text] [Related]
10. Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication.
Grouse JR; Allan MC; Elam MB
J Clin Pharmacol; 2002 Dec; 42(12):1291-8. PubMed ID: 12463722
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells.
Cone J; Wang S; Tandon N; Fong M; Sun B; Sakurai K; Yoshitake M; Kambayashi J; Liu Y
J Cardiovasc Pharmacol; 1999 Oct; 34(4):497-504. PubMed ID: 10511123
[TBL] [Abstract][Full Text] [Related]
12. Cilostazol.
Sorkin EM; Markham A
Drugs Aging; 1999 Jan; 14(1):63-71; discussion 72-3. PubMed ID: 10069409
[TBL] [Abstract][Full Text] [Related]
13. [The mode of action and clinical applications of phosphodiesterase inhibitors as anti-platelet drugs].
Murohara Y; Takatsu Y; Yui Y; Kawai C
Nihon Rinsho; 1989 Apr; 47(4):935-9. PubMed ID: 2545947
[No Abstract] [Full Text] [Related]
14. Cilostazol: new drug. Intermittent claudication: too little efficacy, too many risks.
Prescrire Int; 2009 Apr; 18(100):56-9. PubMed ID: 19585717
[TBL] [Abstract][Full Text] [Related]
15. [Microcirculation in peripheral arterial occlusive diseases will improve. Prostaglandin can prevent surgery].
MMW Fortschr Med; 2003 Dec; 145(51-52):41. PubMed ID: 14974333
[No Abstract] [Full Text] [Related]
16. Cilostazol: a replacement for pentoxifylline?
Shukla V
Issues Emerg Health Technol; 1999 Jul; (7):1-4. PubMed ID: 11811214
[No Abstract] [Full Text] [Related]
17. Cilostazol: a review of its use in intermittent claudication.
Chapman TM; Goa KL
Am J Cardiovasc Drugs; 2003; 3(2):117-38. PubMed ID: 14727939
[TBL] [Abstract][Full Text] [Related]
18. The vascular effects of cilostazol.
Weintraub WS
Can J Cardiol; 2006 Feb; 22 Suppl B(Suppl B):56B-60B. PubMed ID: 16498513
[TBL] [Abstract][Full Text] [Related]
19. [Selective type III phosphodiesterase inhibitor as an antithrombotic agent].
Kimura Y
Nihon Yakurigaku Zasshi; 1995 Sep; 106(3):205-16. PubMed ID: 8529965
[TBL] [Abstract][Full Text] [Related]
20. [Effects of ligustrazine on blood vessels and blood components].
Yan F; Luo R
Zhong Yao Cai; 2002 Feb; 25(2):143-5. PubMed ID: 14740662
[No Abstract] [Full Text] [Related]
[Next] [New Search]
